课题基金 / 基金详情

Targeted nanoparticle delivery of agents to the placenta to treat preeclampsia

Targeted nanoparticle delivery of agents to the placenta to treat preeclampsia
将药物靶向纳米颗粒递送至胎盘以治疗先兆子痫
批准号:
nhmrc : 1150828
负责人:
金额:
$8.55万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Postgraduate Scholarships
财政年份:
2018
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2018-01-01 至 2021-12-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
先兆子痫是妊娠最严重的并发症之一,约占所有妊娠的3%-8%。遗憾的是,目前还没有治疗方法。我们已经开发了一种新的技术,只对胎盘进行治疗,使母亲和婴儿免受副作用。我们将在实验室的小鼠模型和人类组织样本中测试这项技术是否可以治疗先兆子痫的来源-胎盘。这项工作可能会为其他妊娠并发症提供新的治疗方法。
英文摘要
Preeclampsia, one of the most serious complications of pregnancy, affects around 3-8% of all pregnancies. Sadly, there is no treatment. We have developed a new technique to deliver treatments only to the placenta, sparing the mother and baby from side effects. We will test whether this technique can treat the source of preeclampsia, the placenta, in mouse models and human tissue samples in the laboratory. This work may offer possibilities of new treatments to other pregnancy complications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金